{"id":3876,"date":"2025-05-28T15:54:48","date_gmt":"2025-05-28T12:54:48","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3876"},"modified":"2025-11-03T20:23:36","modified_gmt":"2025-11-03T17:23:36","slug":"entrada-therapeutics-receives-eu-authorization-to-start-exon-45-skipping-clinical-trial-in-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/zh\/entrada-therapeutics-receives-eu-authorization-to-start-exon-45-skipping-clinical-trial-in-duchenne-muscular-dystrophy\/","title":{"rendered":"Entrada Therapeutics \u83b7\u5f97\u6b27\u76df\u6388\u6743\uff0c\u5f00\u5c55\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u5916\u663e\u5b50 45 \u8df3\u8dc3\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics \u4eca\u5929\u5ba3\u5e03\uff0c\u5b83\u5df2\u6839\u636e\u6b27\u76df\u4e34\u5e8a\u8bd5\u9a8c\u6761\u4f8b (EU-CTR) \u83b7\u5f97\u591a\u4e2a\u56fd\u5bb6\u536b\u751f\u5f53\u5c40\u548c\u4f26\u7406\u59d4\u5458\u4f1a\u7684\u6388\u6743\uff0c\u542f\u52a8 ELEVATE-45-201\uff0c\u8fd9\u662f\u4e00\u9879\u9488\u5bf9\u9002\u5408\u5916\u663e\u5b50 45 \u8df3\u8dc3\u6cbb\u7597\u7684\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD) \u60a3\u8005\u7684 ENTR-601-45 \u7684 1\/2 \u671f\u591a\u6b21\u9012\u589e\u5242\u91cf (MAD) \u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Entrada Therapeutics\u83b7\u5f97\u6b27\u76df\u6388\u6743<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Entrada Therapeutics \u9996\u5e2d\u6267\u884c\u5b98 Dipal Doshi \u8868\u793a\uff1a\u201cELEVATE-45-201 \u662f\u4e00\u9879\u6700\u5148\u8fdb\u7684\u4e34\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u7814\u7a76\u4e00\u79cd\u5171\u8f6d\u5916\u663e\u5b50\u8df3\u8dc3\u7597\u6cd5\uff0c\u9002\u7528\u4e8e\u9002\u5408\u63a5\u53d7 45 \u53f7\u5916\u663e\u5b50\u8df3\u8dc3\u7597\u6cd5\u7684\u4e2a\u4f53\uff0c\u6709\u671b\u89e3\u51b3\u5927\u91cf\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u60a3\u8005\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u201d \u201c\u6b27\u76df\u7684\u6279\u51c6\u5efa\u7acb\u5728\u6211\u4eec\u65b0\u578b\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u9879\u76ee\u65e5\u76ca\u589e\u957f\u7684\u4e34\u5e8a\u53d1\u5c55\u52bf\u5934\u4e4b\u4e0a\u3002\u968f\u7740 ELEVATE-44 \u548c ELEVATE-45 \u8fd1\u671f\u83b7\u5f97\u6279\u51c6\uff0c\u4ee5\u53ca\u8ba1\u5212\u4e8e\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u63d0\u4ea4\u7684 ELEVATE-50 \u7533\u8bf7\uff0c\u6211\u4eec\u6709\u671b\u5728\u5e74\u5e95\u524d\u5927\u5e45\u6269\u5c55\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD) \u7684\u7279\u8bb8\u7ecf\u8425\u8303\u56f4\u3002\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u9605\u8bfb\u66f4\u591a\uff1a<\/strong> <a href=\"https:\/\/dmdwarrior.com\/zh\/next-generation-exon-skipping-therapies-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"post\" data-id=\"2468\" rel=\"noreferrer noopener\">\u4e3a\u6cbb\u7597\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u800c\u5f00\u53d1\u7684\u4e0b\u4e00\u4ee3\u5916\u663e\u5b50\u8df3\u8dc3\u7597\u6cd5<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u6b27\u76df\u542f\u52a8\u5916\u663e\u5b5045\u8df3\u8dc3\u4e34\u5e8a\u8bd5\u9a8c<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-45-201\u662f\u4e00\u9879\u5168\u7403\u6027\u3001\u4e24\u90e8\u5206\u3001\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u76841\/2\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30ENTR-601-45\u5bf9\u53ef\u8fdb\u884c\u5916\u663e\u5b5045\u8df3\u8dc3\u6cbb\u7597\u7684\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u95e8\u8bca\u60a3\u8005\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u6709\u6548\u6027\u3002A\u90e8\u5206\u662f\u4e00\u9879\u591a\u5242\u91cf\u9012\u589e\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30\u7ea624\u4f8b\u60a3\u8005\u7684\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u836f\u6548\u52a8\u529b\u5b66\uff0c\u5305\u62ec\u5916\u663e\u5b50\u8df3\u8dc3\u548c\u808c\u8425\u517b\u4e0d\u826f\u86cb\u767d\u7684\u4ea7\u751f\u3002\u7ed9\u836f\u5c06\u6bcf\u516d\u5468\u8fdb\u884c\u4e00\u6b21\uff0c\u4e09\u4e2a\u961f\u5217\u7684\u8ba1\u5212\u5242\u91cf\u9884\u8ba1\u57285\u6beb\u514b\/\u5343\u514b\u81f315\u6beb\u514b\/\u5343\u514b\u4e4b\u95f4\u3002B\u90e8\u5206\u5c06\u8fdb\u4e00\u6b65\u8bc4\u4f30A\u90e8\u5206\u4e2d\u786e\u5b9a\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u7684\u6700\u4f73\u5242\u91cf\uff0c\u5305\u62ec\u529f\u80fd\u7ed3\u679c\u548c\u60a3\u8005\u62a5\u544a\u7684\u751f\u6d3b\u8d28\u91cf\u6307\u6807\u3002\u7814\u7a76\u53c2\u4e0e\u8005\u53ef\u80fd\u6709\u8d44\u683c\u53c2\u52a0\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u6269\u5c55\u7814\u7a76(OLE)\uff0c\u5728\u8be5\u7814\u7a76\u4e2d\uff0c\u5c06\u5728\u66f4\u957f\u7684\u65f6\u95f4\u5185\u8bc4\u4f30ENTR-601-45\u7684\u5b89\u5168\u6027\u3001\u6709\u6548\u6027\u548c\u8010\u53d7\u6027\u3002\u8be5\u516c\u53f8\u6709\u671b\u4e8e 2025 \u5e74\u7b2c\u4e09\u5b63\u5ea6\u542f\u52a8 ELEVATE-45-201\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u9605\u8bfb\u66f4\u591a<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/zh\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7\u4e34\u5e8a\u8bd5\u9a8c\uff08\u6240\u6709\u7814\u7a76\u5217\u8868\uff09<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics, today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3881,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,91,321,234,317,318,319],"class_list":["post-3876","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-ema","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/3876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/comments?post=3876"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/3876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media\/3881"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media?parent=3876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/categories?post=3876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/tags?post=3876"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}